AdaptHealth delivered strong financial results in the third quarter of 2025, exceeding expectations with a 1.8% increase in net revenue to $820.3 million and a 7% rise in net income to $24.5 million. The company also achieved its highest organic revenue growth since Q1 2024 and reduced debt by $50 million.

AdaptHealth delivered solid results in the second quarter of 2025, with net revenue of $800.4 million. While net revenue and adjusted EBITDA saw slight decreases year-over-year, the company highlighted progress in driving revenue growth through new partnerships, improving operating efficiency, and reducing debt.

AdaptHealth Corp. announced its first quarter 2025 financial results, reporting a net revenue of $777.9 million, a 1.8% decrease compared to the previous year. The company experienced a net loss of $7.2 million and a 19.3% decrease in Adjusted EBITDA to $127.9 million. Despite these declines, cash flow from operations significantly increased to $95.5 million.

AdaptHealth reported a slight decrease in net revenue for Q4 2024, but net income increased significantly compared to the previous year. The company is focusing on key initiatives like the One Adapt program and leveraging AI to drive long-term success.

AdaptHealth Corp. reported a net revenue increase of 0.2% to $805.9 million compared to $804.0 million. Net income attributable to AdaptHealth Corp. was $22.9 million, a significant improvement from the net loss of $454.1 million in the same quarter of the previous year. Adjusted EBITDA increased by 1.9% to $164.3 million. The company has updated its financial guidance for fiscal year 2024.

AdaptHealth Corp. reported a 1.6% increase in net revenue, reaching $806.0 million, and a 39.0% increase in net income attributable to AdaptHealth Corp., which was $19.4 million.

AdaptHealth Corp. reported a 6.4% increase in net revenue to $792.5 million and an 18.3% increase in Adjusted EBITDA to $158.5 million. However, the company experienced a net loss of $2.1 million, contrasting with a net income of $15.7 million in the same quarter of the previous year. Free cash flow was $(38.9) million, a decrease from $51.1 million.

AdaptHealth Corp. reported a 10.0% increase in net revenue to $858.2 million and a significant rise in adjusted EBITDA to $204.6 million for Q4 2023. The company experienced a net loss of $254.5 million, largely due to a goodwill write-down. Free cash flow improved to $66.6 million.

AdaptHealth Corp. reported a 6.3% increase in net revenue to $804.0 million compared to $756.5 million in the same quarter last year, driven by sleep products. However, the company experienced a net loss of $454.1 million, primarily due to a $511.9 million pre-tax write down of goodwill. Adjusted EBITDA saw a slight increase of 0.6% to $161.2 million, while cash flow from operations and free cash flow also increased year-to-date.

AdaptHealth Corp. reported a 9.0% increase in net revenue to $793.3 million for Q2 2023, driven by strength in Sleep and Respiratory product lines. Net income attributable to AdaptHealth Corp. remained consistent at $14.0 million. The company is updating its financial guidance for fiscal year 2023.

AdaptHealth Corp. reported a 5.4% increase in net revenue to $744.6 million compared to the first quarter of 2022, with a notable 17.6% growth in the Sleep business. Net income attributable to AdaptHealth Corp. was $15.7 million. The company is implementing a cost management program to revamp supply chain infrastructure and restructure the operating model.

AdaptHealth's Q4 2022 results showed an 11.1% increase in net revenue compared to Q4 2021, driven by non-acquired growth of 5.3%. However, the company reported a net loss attributable to AdaptHealth Corp. of $2.6 million, and Adjusted EBITDA decreased by 7.7% compared to the same period last year. The company updated its financial guidance for fiscal year 2023.

AdaptHealth Corp. reported a solid third quarter, capitalizing on strong demand in HME and Sleep product lines, with CPAP patient set-ups near record levels and double-digit growth in the diabetes product line. Operational excellence initiatives partially offset inflationary pressures, leading to sequential margin expansion.

AdaptHealth reported its Q2 2022 results, highlighting resilience in HME and Sleep product lines with CPAP patient setups near record levels and a 16% increase in rental census from February levels. The diabetes product line also posted double-digit growth. The company maintains its fiscal year 2022 guidance.

AdaptHealth reported strong first-quarter results, driven by continued strength in the diabetes product line and resilient HME product line. The company is updating its previously issued financial guidance for fiscal year 2022 and announced the authorization of a share repurchase program for up to $200 million.

AdaptHealth announced financial results for the fourth quarter and fiscal year ended December 31, 2021. The company highlighted its continued growth and prosperity despite the pandemic, CPAP equipment shortage, and supply chain challenges. They were pleased with their free cash flow generation as they exited the year.

AdaptHealth reported record revenue of $627.6 million, a 43% increase year-over-year. Adjusted EBITDA was $135.3 million, up 36% year-over-year. The company raised its full-year guidance, reflecting confidence in continued growth.

AdaptHealth Corp. announced strong financial results for the second quarter, driven by the full quarter impact of AeroCare and realization of integration synergies. The company is experiencing organic growth and making strategic acquisitions. They are also increasing financial guidance for fiscal year 2021.

AdaptHealth Corp. reported strong Q1 2021 financial results, driven by the dedication of its employees and the successful integration of AeroCare. The company is increasing its financial guidance for fiscal year 2021.

AdaptHealth Corp. announced financial results for the fourth quarter and full year ended December 31, 2020. The company is increasing its previously issued financial guidance for fiscal year 2021.

AdaptHealth Corp. reported strong third-quarter results, driven by employee dedication and strategic acquisitions, leading to increased financial guidance for fiscal year 2020.

AdaptHealth's Q2 2020 performance reflected the team's hard work and the successful deployment of a scalable growth model. The COVID-19 pandemic presented challenges, offset by new business opportunities and growth in other product categories.

AdaptHealth Corp. reported a strong first quarter despite COVID-19 challenges, driven by the team's hard work and the company's scalable growth model. The HME business performed well, and two accretive HME business acquisitions were closed and fully integrated. PCS generated $33.9 million in net revenue, with progress made in addressing issues and growth expected in continuous glucose monitoring.

AdaptHealth announced financial results for the fourth quarter and full year ended December 31, 2019. The company reported record net revenues, Adjusted EBITDA, and Adjusted EBITDA less Patient Equipment Capex in Q4 2019.